WASHINGTON — President Trump’s nominee to lead the health department, Robert F. Kennedy Jr., invested in gene-editing technology and is owed substantial advances for several books, according to financial disclosures released ahead of his confirmation hearings.
The disclosures give the clearest view to date of RFK Jr.’s investments, employment, and potential conflicts of interest. They show that he plans to divest stock holdings, including stakes in biotech firms CRISPR Therapeutics AG and Dragonfly Therapeutics. He’s also stepping down from roles at his law firm and at the anti-vaccine nonprofit Children’s Health Defense.
Trump tapped RFK Jr. to lead the Department of Health and Human Services after Kennedy ended his presidential campaign and endorsed Trump. Confirmation hearings haven’t yet been scheduled.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in